InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.205 0.005 (2.38%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$123 Trading Halt 10 Sep 2020 8:27AM $0.740 $0.205 fallen by 72.30%
$123 Dimerix Awarded $1 Million MRFF Funding 3 Sep 2020 9:19AM $0.700 $0.205 fallen by 70.71%
$123 Notice of Annual General Meeting/Proxy Form 1 Sep 2020 9:21AM $0.740 $0.205 fallen by 72.30%
$123 Annual General Meeting - Notice and Letter to Shareholders 1 Sep 2020 9:17AM $0.740 $0.205 fallen by 72.30%
$123 Appendix 4G and Corporate Governance Statement 27 Aug 2020 9:02AM $0.585 $0.205 fallen by 64.96%
$123 Annual Report to shareholders 27 Aug 2020 9:00AM $0.585 $0.205 fallen by 64.96%
$123 Preliminary Final Report 27 Aug 2020 8:53AM $0.585 $0.205 fallen by 64.96%
$123 Investor Presentation 29 Jul 2020 9:48AM $0.380 $0.205 fallen by 46.05%
$123 Positive Top-Line Results in FSGS Phase 2a Clinical Study 29 Jul 2020 9:01AM $0.380 $0.205 fallen by 46.05%
$123 Trading Halt 27 Jul 2020 8:27AM $0.380 $0.205 fallen by 46.05%
$123 Last Patient Completes Dosing in DKD Phase 2 Clinical Study 24 Jul 2020 9:21AM $0.380 $0.205 fallen by 46.05%
$123 Change in substantial holding 20 Jul 2020 8:23AM $0.335 $0.205 fallen by 38.81%
$123 Quarterly Appendix 4C and Activities Report 14 Jul 2020 9:10AM $0.365 $0.205 fallen by 43.84%
$123 DMX-700 Program for COPD Advances 6 Jul 2020 9:19AM $0.375 $0.205 fallen by 45.33%
$123 Cleansing Notice 29 Jun 2020 8:23AM $0.355 $0.205 fallen by 42.25%
$123 Appendix 2A 29 Jun 2020 8:23AM $0.355 $0.205 fallen by 42.25%
$123 Proposed issue of Securities - DXB 22 Jun 2020 9:47AM $0.440 $0.205 fallen by 53.41%
$123 Dimerix Completes $5.8m Placement 22 Jun 2020 9:46AM $0.440 $0.205 fallen by 53.41%
$123 Trading Halt 18 Jun 2020 8:52AM $0.440 $0.205 fallen by 53.41%
$123 Last Patient Completes Dosing in FSGS Phase 2 Clinical Study 17 Jun 2020 9:19AM $0.410 $0.205 fallen by 50%
$123 Investor Presentation 4 Jun 2020 9:43AM $0.270 $0.205 fallen by 24.07%
$123 Global REMAP-CAP Platform Trial Protocol To Include DMX-200 4 Jun 2020 8:37AM $0.270 $0.205 fallen by 24.07%
$123 Trading Halt 2 Jun 2020 9:32AM $0.270 $0.205 fallen by 24.07%
$123 Dimerix to Present at NWR Virtual Health Conference 1 May 2020 9:56AM $0.200 $0.205 risen by 2.50%
$123 Quarterly Appendix 4C and Activities Report 21 Apr 2020 9:26AM $0.150 $0.205 risen by 36.67%

476 - 500 of 743 results

Page 20 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.